{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T21:23:53Z","timestamp":1789939433267,"version":"4.0.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Lymphoma SPORE","award":["CA136411"],"award-info":[{"award-number":["CA136411"]}]},{"name":"Leukemia and Lymphoma Society Translational Research Award"},{"name":"Cancer Center Support","award":["CA16672"],"award-info":[{"award-number":["CA16672"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.clml.2013.05.024","type":"journal-article","created":{"date-parts":[[2013,11,30]],"date-time":"2013-11-30T15:56:00Z","timestamp":1385826960000},"page":"S355-S362","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"S2","title":["Combination of Pim Kinase Inhibitor SGI-1776 and Bendamustine in B-Cell Lymphoma"],"prefix":"10.1016","volume":"13","author":[{"given":"Qingshan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa S.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sattva S.","family":"Neelapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varsha","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2013.05.024_bib1","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/j.bcp.2010.07.039","article-title":"Inflammation and survival pathways: chronic\u00a0lymphocytic leukemia as a model system","volume":"80","author":"Chen","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.clml.2013.05.024_bib2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrc2986","article-title":"For better or for worse: the role of Pim oncogenes in tumorigenesis","volume":"11","author":"Nawijn","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clml.2013.05.024_bib3","doi-asserted-by":"crossref","first-page":"4809","DOI":"10.1038\/onc.2008.123","article-title":"Pim kinase-dependent inhibition of c-Myc degradation","volume":"27","author":"Zhang","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.clml.2013.05.024_bib4","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/sj.onc.1201288","article-title":"Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc","volume":"15","author":"Allen","year":"1997","journal-title":"Oncogene"},{"key":"10.1016\/j.clml.2013.05.024_bib5","doi-asserted-by":"crossref","first-page":"448","DOI":"10.18632\/oncotarget.283","article-title":"The direct Myc target Pim3 cooperates with other Pim kinases in supporting viability of Myc-induced B-cell lymphomas","volume":"2","author":"Forshell","year":"2011","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2013.05.024_bib6","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/ncb1618","article-title":"PIM1-dependent phosphorylation of histone H3 at serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformation","volume":"9","author":"Zippo","year":"2007","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.clml.2013.05.024_bib7","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1101\/gad.912401","article-title":"Hierarchical phosphorylation of the translation inhibitor 4E-BP1","volume":"15","author":"Gingras","year":"2001","journal-title":"Genes Dev"},{"key":"10.1016\/j.clml.2013.05.024_bib8","doi-asserted-by":"crossref","first-page":"45358","DOI":"10.1074\/jbc.M307933200","article-title":"The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death","volume":"278","author":"Yan","year":"2003","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.clml.2013.05.024_bib9","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.biocel.2005.10.010","article-title":"The oncogenic serine\/threonine kinase Pim-1 directly phosphorylates and activates the G2\/M specific phosphatase Cdc25C","volume":"38","author":"Bachmann","year":"2006","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.clml.2013.05.024_bib10","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1182\/blood-2006-11-060350","article-title":"Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas","volume":"110","author":"Lwin","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.05.024_bib11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0167-4889(02)00347-6","article-title":"Phosphorylation of the cell cycle inhibitor p21Cip1\/WAF1 by Pim-1 kinase","volume":"1593","author":"Wang","year":"2002","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.clml.2013.05.024_bib12","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1182\/blood-2009-03-212852","article-title":"Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells","volume":"114","author":"Chen","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.05.024_bib13","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1182\/blood-2010-12-323022","article-title":"Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia","volume":"118","author":"Chen","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.05.024_bib14","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1080\/10428190802419640","article-title":"Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study","volume":"49","author":"Hsi","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2013.05.024_bib15","doi-asserted-by":"crossref","first-page":"5517","DOI":"10.1182\/blood-2011-03-344374","article-title":"PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma","volume":"118","author":"Gomez-Abad","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.05.024_bib16","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1182\/blood-2012-02-412643","article-title":"Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma","volume":"120","author":"Yang","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.05.024_bib17","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1182\/blood-2004-09-3706","article-title":"Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival","volume":"105","author":"Hammerman","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.05.024_bib18","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1158\/1078-0432.CCR-07-1061","article-title":"Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents","volume":"14","author":"Leoni","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"suppl 1","key":"10.1016\/j.clml.2013.05.024_bib19","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1053\/j.seminhematol.2011.03.004","article-title":"Bendamustine's emerging role in the management of lymphoid malignancies","volume":"48","author":"Rummel","year":"2011","journal-title":"Semin Hematol"},{"key":"10.1016\/j.clml.2013.05.024_bib20","doi-asserted-by":"crossref","first-page":"7456","DOI":"10.1158\/1078-0432.CCR-08-3041","article-title":"Bendamustine in B-cell malignancies: the new 46-year-old kid on the block","volume":"15","author":"Gandhi","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"suppl 1","key":"10.1016\/j.clml.2013.05.024_bib21","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1053\/j.seminhematol.2011.03.003","article-title":"Mechanism of action: the unique pattern of bendamustine-induced cytotoxicity","volume":"48","author":"Leoni","year":"2011","journal-title":"Semin Hematol"},{"issue":"suppl 1","key":"10.1016\/j.clml.2013.05.024_bib22","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.3816\/CLM.2007.s.028","article-title":"Bendamustine in non-Hodgkin lymphoma: the double-agent that came from the Cold War","volume":"8","author":"Forero-Torres","year":"2007","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.clml.2013.05.024_bib23","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1007\/s00277-012-1503-5","article-title":"Treatment option of bendamustine in combination with rituximab in elderly and frail patients with aggressive B-non-Hodgkin lymphoma: rational, efficacy, and tolerance","volume":"91","author":"Horn","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2013.05.024_bib24","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"Lenz","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.05.024_bib25","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.critrevonc.2010.09.003","article-title":"Mantle cell lymphoma: the promise of new treatment options","volume":"80","author":"Goy","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clml.2013.05.024_bib26","doi-asserted-by":"crossref","first-page":"424","DOI":"10.5858\/2003-127-0424-COMCLC","article-title":"Characterization of 4 mantle cell lymphoma cell lines","volume":"127","author":"Amin","year":"2003","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.clml.2013.05.024_bib27","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00432-007-0278-x","article-title":"Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: the role of ATM-Chk2-Cdc25A and ATM-p53-p21-pathways","volume":"134","author":"Gaul","year":"2008","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.clml.2013.05.024_bib28","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2010-04-189977","article-title":"Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era","volume":"117","author":"Perez-Galan","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.05.024_bib29","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1139\/o06-072","article-title":"GammaH2AX and its role in DNA double-strand break repair","volume":"84","author":"Fillingham","year":"2006","journal-title":"Biochem Cell Biol"},{"key":"10.1016\/j.clml.2013.05.024_bib30","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S0960-9822(00)00610-2","article-title":"A\u00a0critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage","volume":"10","author":"Paull","year":"2000","journal-title":"Curr Biol"},{"key":"10.1016\/j.clml.2013.05.024_bib31","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.4161\/cc.10.22.18288","article-title":"Targeted cancer therapy: what if the driver is just a messenger?","volume":"10","author":"Schatz","year":"2011","journal-title":"Cell Cycle"},{"key":"10.1016\/j.clml.2013.05.024_bib32","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1073\/pnas.1013214108","article-title":"The Pim protein kinases regulate energy metabolism and cell growth","volume":"108","author":"Beharry","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2013.05.024_bib33","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1158\/1538-7445.AM2012-2796","article-title":"Efficacy and biomarker modulation by AZD1208, a novel, potent and selective pan-Pim kinase inhibitor, in models of acute myeloid leukemia","volume":"72","author":"Keeton","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2013.05.024_bib34","doi-asserted-by":"crossref","unstructured":"Keeton E, Palakurthi S, Alimzhanov M, et\u00a0al. AZD1208, a novel, potent and selective pan Pim kinase inhibitor, demonstrates efficacy in models of acute myeloid leukemia. Paper presented at the 53rd ASH Annual Meeting, December 10-13, 2011; San Diego, CA. Abstract\u00a01540.","DOI":"10.1182\/blood.V118.21.1540.1540"},{"key":"10.1016\/j.clml.2013.05.024_bib35","doi-asserted-by":"crossref","unstructured":"Munugalavadla V, Berry L, Chen Y-H, et al. A selective PIM kinase inhibitor is highly active in multiple myeloma: mechanism of action and signal transduction studies. 53rd ASH Annual Meeting Abstracts 2011: abstract 4084.","DOI":"10.1182\/blood.V116.21.4084.4084"},{"key":"10.1016\/j.clml.2013.05.024_bib36","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.bcp.2012.09.018","article-title":"Pim kinases in cancer: Diagnostic, prognostic and treatment opportunities","volume":"85","author":"Blanco-Aparicio","year":"2013","journal-title":"Biochem Pharmacol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265013002413?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265013002413?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:24:40Z","timestamp":1761870280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265013002413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":36,"alternative-id":["S2152265013002413"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2013.05.024","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination of Pim Kinase Inhibitor SGI-1776 and Bendamustine in B-Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2013.05.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}